Jeffrey Tamsing, MD
Neurology · Parker, CONPI 1457518680
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $127,259 of the $179,625 with a category attached, or 70.8%. 60 manufacturers reported payments, led by AstraZeneca at 49.8% of the total. Reporting peaked in 2019 at $54,800 and has fallen 66.5% since, to $18,352 in 2025. Among neurology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,776 payments — averaging $101.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$89K
- Lilly USA, LLC$39K
- Argenx US, Inc.$25K
- AbbVie$4K
- Amgen$3K
- UCB, Inc.$1K
- plus $17K from 54 others
What the payments were for
- Consulting fees$13,5708%
- Speaking & faculty fees$127,25971%
- Travel & lodging$8,1185%
- Food & beverage$30,52917%
- Education$1490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$179,625 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 46 | $631,887 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 38 | $264,807 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 22 | $97,023 |
| UbrelvyUbrogepant | 30 | $37,585 |
| Nurtec OdtRimegepant Sulfate | 17 | $21,852 |
| BotoxOnabotulinumtoxina | 16 | $21,126 |
| Invega SustennaPaliperidone Palmitate | 12 | $20,299 |
| Emgality PenGalcanezumab-Gnlm | 21 | $17,862 |
| Topiramate ErTopiramate | 13 | $8,511 |
| Frovatriptan Succinate | 13 | $4,765 |
| Gabapentin | 143 | $4,191 |
| Mycophenolate Mofetil | 12 | $2,871 |
| Pyridostigmine Bromide | 19 | $2,138 |
| Armodafinil | 15 | $1,918 |
| Duloxetine Hcl | 59 | $1,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen, Hizentra | $346 | $361,83060 claims |
| AbbVieUbrelvy, Botox | $3,965 | $58,71146 claims |
| PfizerNurtec Odt | $1,208 | $21,85217 claims |
| Johnson & JohnsonInvega Sustenna | $321 | $20,29912 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $81 | $5,00831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 neurology providers in Colorado.
Other neurology in Parker
- Ravi ShahParker$1.3M
- Tamara MillerFort Collins$1.4M
- Justin MoonDenver$1.4M
- Rajeev KumarEnglewood$955K
- Marc TreihaftEnglewood$673K
- Jeffrey BennettAurora$605K
- Beverly GilderLone Tree$558K
- Michael AmentDenver$457K
- Enrique AlvarezAurora$407K
- Adam WolffDenver$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.